The Community Practice Research Core, formerly the Community Practice Core, enables Dana-Farber/Harvard Cancer Center researchers to conduct cancer-related projects in real-world community settings. The Core provides easy access to a racially diverse population of over 11,000,000 patients within the local and national community-based clinical practices of Harvard Vanguard Medical Associates (HVMA)/Atrius Health, Harvard Pilgrim Health Care and HMO Cancer Research Network. Harvard Vanguard Medical Associates is a non-profit, multi-specialty medical group practice providing care to more than 480,000 adult and pediatric patients at over 21 offices across eastern Massachusetts. It is one of five medical groups that comprise Atrius Health. All Atrius groups share a single electronic medical record system (EPIC?), easing researchers'access to its 600,000 patients. Harvard Pilgrim Health Care is a non-profit health plan that provides medical insurance to more than 1,000,000 members in Massachusetts, New Hampshire and Maine. Cancer Research Network is an NCI-funded consortium of 14 integrated healthcare systems, representing 11,000,000 enrollees across the United States. This facility has been continuously funded by the CCSG since 2000. Director: Larissa Nekhlyudov, MD, MPH(HMS) Category: 3.01, 3.03 and 3.06 (Population Research) Management: Cancer Center managed

Public Health Relevance

The Core conducts research on cancer prevention, detection, treatment, long-term care, surveillance and survivorship. The populations that this core accesses are ideal for studies that involve basic, clinical and population sciences that address issues impacting diverse communities;need large samples of patients and/or providers;examine preventive strategies;include rare cancers;investigate the dissemination of proven technologies and interventions;and focus on cancer prevention.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006516-47
Application #
8228370
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-15
Budget End
2012-11-30
Support Year
47
Fiscal Year
2012
Total Cost
$191,811
Indirect Cost
$69,347
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Hu, Yanhui; Comjean, Aram; Roesel, Charles et al. (2016) FlyRNAi.org-the database of the Drosophila RNAi screening center and transgenic RNAi project: 2017 update. Nucleic Acids Res :
Hong, Theodore S; Wo, Jennifer Y; Yeap, Beow Y et al. (2016) Multi-Institutional Phase II Study of High-Dose Hypofractionated Proton Beam Therapy in Patients With Localized, Unresectable Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. J Clin Oncol 34:460-8
Freedman, Rachel A; Gelman, Rebecca S; Wefel, Jeffrey S et al. (2016) Translational Breast Cancer Research Consortium (TBCRC) 022: A Phase II Trial of Neratinib for Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases. J Clin Oncol 34:945-52
Mohr, Stephanie E; Hu, Yanhui; Ewen-Campen, Benjamin et al. (2016) CRISPR guide RNA design for research applications. FEBS J 283:3232-8
Brunner, Andrew M; Li, Shuli; Fathi, Amir T et al. (2016) Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission. Br J Haematol 175:496-504
Cox, Andrew G; Hwang, Katie L; Brown, Kristin K et al. (2016) Yap reprograms glutamine metabolism to increase nucleotide biosynthesis and enable liver growth. Nat Cell Biol 18:886-96
McKay, Tina B; Hjortdal, Jesper; Sejersen, Henrik et al. (2016) Endocrine and Metabolic Pathways Linked to Keratoconus: Implications for the Role of Hormones in the Stromal Microenvironment. Sci Rep 6:25534
Nelms, Bradlee D; Waldron, Levi; Barrera, Luis A et al. (2016) CellMapper: rapid and accurate inference of gene expression in difficult-to-isolate cell types. Genome Biol 17:201
Tan, Justin L; Fogley, Rachel D; Flynn, Ryan A et al. (2016) Stress from Nucleotide Depletion Activates the Transcriptional Regulator HEXIM1 to Suppress Melanoma. Mol Cell 62:34-46
Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381

Showing the most recent 10 out of 303 publications